Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40...

Full description

Bibliographic Details
Main Authors: Wander, P., Cheung, Laurence, Pinhan̉«os, S.S., Jones, L., Kerstjens, M., Arentsen-Peters, S.T.C.J.M., Singh, S., Chua, G.A., Castro, P.G., Schneider, P., Dolman, M.E.M., Koopmans, B., Molenaar, J.J., Pieters, R., Zwaan, C.M., Kotecha, Rishi, Stam, R.W.
Format: Journal Article
Language:English
Published: 2020
Online Access:http://hdl.handle.net/20.500.11937/79575
Description
Summary:The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40% [2]. MLL-rearranged infant ALL is both clinically and biologically distinct from other childhood ALL subtypes, which is reflected by a unique gene expression profile [3], a remarkably silent mutational landscape [4], and pronounced resistance to currently applied chemotherapeutics [5].

Similar Items